Elekta Ltd and Medical Intelligence Medizintechnik GmbH defend claims by humediQ GmbH

CRAWLEY, UK, December 2, 2014 – humediQ GmbH has initiated legal proceedings
against two companies in the Elekta (EKTA-B.ST) group.
The dispute relates to an agreement from October 2011 for exclusive supply of
Identify™ under the Elekta label. Identify is a patient identification and setup
verification product.

Recently, a dispute arose between Elekta and humediQ relating to certain terms
of the agreement. Now, humediQ is claiming damages from Elekta for an amount of
approximately EUR 16 million.

Elekta believes that the claims have no merit and intends to defend them
vigorously and assert counterclaims against humediQ.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 20:00 CET on December 2, 2014.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.